Marcia K. Horn is the president and CEO of ICAN, International Cancer Advocacy Network, https://askican.org/
At ICAN, Marcia is a research advocate who has directly navigated patient cases pan-tumor since the founding of the organization in 1996. She is also a molecular profiling advocate, a clinical trials matching advocate, an expanded access program advocate, a public policy advocate, and a health equity advocate.
Since March 2017, Marcia has served as the Executive Director of the Exon 20 Group (https://exon20group.org/), an international multi-stakeholder coalition created to transform cancers caused by rare and lethal insertion mutations into manageable and survivable conditions. The Exon 20 Group provides more than 20 services to patients, care partners, and additional stakeholders and recently launched an International Research Consortium and Knowledge Bank project.
Marcia is one of the two research advocates selected for both the Stand Up 2 Cancer Molecular Early Detection of Colon Cancer Dream Team and the Stand Up 2 Cancer InTIME Dream Team for Lung Cancer Interception. She served for three years as DIA’s inaugural chairman of its Patient Engagement Community and is a PCORI Ambassador. Marcia is a member of the ASCO TAPUR Study Molecular Tumor Board, the Banner Health Institutional Review Board, and the SWOG Early Therapeutics/Rare Cancers Committee. She is a research advocate for the National Cancer Institute’s University of Texas Southwestern Medical Center Lung Cancer SPORE (Specialized Program of Research Excellence).
Marcia graduated Phi Beta Kappa from Stanford University in Political Science and received her JD from the Stanford Law School. Before joining ICAN, she practiced litigation and appellate law in Phoenix.